Rhabdoid tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:23:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Rhabdoid tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of CEB-01 for Children with Resectable Tumors https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ceb-01-for-children-with-resectable-tumors/ Wed, 29 Apr 2026 15:04:35 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ceb-01-for-children-with-resectable-tumors/ This clinical trial is focused on studying certain types of childhood cancers, specifically those that can be surgically removed from the abdomen. The cancers being studied include extracranial malignant rhabdoid tumor, desmoplastic small round cell tumor, germ cell tumor, Wilms tumor, synovial sarcoma, high-risk neuroblastoma, soft-tissue sarcoma, and fibrolamellar hepatocellular carcinoma. The treatment being tested is a new formulation called CEB-01, which contains the active substance 7-ethyl-10-hydroxycamptothecin. This substance is delivered through a special material that can be implanted in the body.

The purpose of the study is to evaluate the safety and tolerability of CEB-01 when used alongside standard cancer treatments. The study will involve children from birth to under 18 years of age who have these specific types of tumors. Participants will receive the new treatment in addition to their usual care, and the effects will be compared to those who receive only the standard treatment. The study will monitor for any side effects and how well the treatment works in preventing the cancer from coming back or spreading.

Throughout the study, researchers will collect information on the participants’ health and how their bodies process the treatment. This includes measuring the levels of the drug in the blood and observing any changes in the tumors. The study aims to provide valuable information on the potential benefits and risks of using CEB-01 in treating these childhood cancers.

]]> Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months – 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors https://clinicaltrials.eu/trial/study-on-ribociclib-topotecan-and-temozolomide-for-children-and-young-adults-12-months-21-years-with-relapsed-or-refractory-neuroblastoma-and-solid-tumors/ Wed, 29 Apr 2026 14:30:04 +0000 https://clinicaltrials.eu/trial/study-on-ribociclib-topotecan-and-temozolomide-for-children-and-young-adults-12-months-21-years-with-relapsed-or-refractory-neuroblastoma-and-solid-tumors/ This clinical trial is focused on studying the treatment of relapsed or refractory neuroblastoma and other solid tumors in children and young adults aged 12 months to 21 years. Neuroblastoma is a type of cancer that forms in certain types of nerve tissue. The study will use a combination of medications, including ribociclib (also known by its code name LEE011), temozolomide, and topotecan hydrochloride. These medications are being tested together to see if they can effectively treat these types of cancers.

The purpose of the study is to assess the safety and effectiveness of this combination of drugs. The study is divided into two phases. In the first phase, researchers will determine the best dose of ribociclib to use with the other medications. In the second phase, the study will further evaluate how well this combination works in treating neuroblastoma compared to a placebo. Participants will receive the medications either orally or through intravenous infusion, depending on the specific drug.

Throughout the study, participants will be closely monitored for any side effects and to see how their tumors respond to the treatment. The study aims to find the most effective and safe way to use these medications together to help treat these challenging cancers in young patients. The trial is expected to continue until 2029, allowing researchers to gather comprehensive data on the treatment’s impact.

]]> Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials https://clinicaltrials.eu/trial/56496/ Wed, 29 Apr 2026 14:29:10 +0000 https://clinicaltrials.eu/trial/56496/ This study focuses on evaluating a medication called tazemetostat, which is given as a film-coated tablet taken by mouth. The study aims to assess the long-term safety of this medication in patients who have previously been treated with tazemetostat in other clinical trials and have shown benefit from the treatment.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

]]>